Compare CNNE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | SLN |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 678.0M |
| IPO Year | 2017 | 2010 |
| Metric | CNNE | SLN |
|---|---|---|
| Price | $14.98 | $12.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $20.25 | ★ $42.60 |
| AVG Volume (30 Days) | 450.2K | ★ 666.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $499,700,000.00 | $559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $127.50 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $4.19 |
| 52 Week High | $19.13 | $17.58 |
| Indicator | CNNE | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 41.52 |
| Support Level | $14.04 | $4.70 |
| Resistance Level | $16.36 | $15.28 |
| Average True Range (ATR) | 0.41 | 0.75 |
| MACD | -0.07 | -0.28 |
| Stochastic Oscillator | 11.91 | 6.92 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.